We have constructed a series of MLV-based retroviral vectors and packaging components expressed from the CMV promoter and carried on plasmids containing SV40 origins of replication. These two features greatly enhanced retroviral gene expression when introduced into cell lines carrying the SV40 large T antigen. The two packaging components, gag-pol and env, were placed on separate plasmids to reduce helper virus formation. Using a highly transfectable human cell line and sodium butyrate to further increase expression of each component, we achieved helper-free viral stocks of -10 7 Infectious units/ml by 48 h after transient co-transfectlon with the three plasmid components. This system can be used both for the generation of high ttter retroviral stocks for transductlon and for the rapid screening of a large number of MLV gag-pol or env mutants.
INTRODUCTION
The generation of high titer retroviral stocks for the efficient transduction of target cells is an important technical goal for a range of gene transfer applications. Most standard methods currently use cell lines expressing the gag-pol and env genes of MLV (the packaging components). These will package a retroviral vector genome introduced by transduction or by transfection with an appropriate plasmid (1) . In order to obtain retroviral stocks of the highest titers, it is necessary to establish additional cell lines that not only contain the gag-pol and env cassettes, but also have the proviral vector genome stably integrated To identify the highest producing lines, many subclones may then need to be screened, as greatly varying titers are observed between different subclones (2, 3) . This screening process can take several weeks and the cell lines so established may lose their packaging ability as they are passaged (4) . A simple system for the production of retroviral stocks without the use of packaging lines has been described by Landau and Littman (5) . This approach exploits the high level of transient expression when COS-7 cells are transfected by plasmids containing SV40 origins of replication by placing both the packaging components and the retroviral vector genome on plasmids carrying such sequences. Following simultaneous transfection of gag-pol, env and vector genome plasmids into COS-7 cells, viral titers of 10 4 infectious units/ml were achieved 48-72 h post-transfection. Retrovirus production by this three-plasmid co-transfection system is a particularly convenient method for the rapid analysis of MLV gag-pol or env mutants and has the advantage of being simple and reproducible in the hands of different operators. However, compared with selected lines, the titers are low.
We report here a simple system for the production of high titer helper-free retroviral vectors in which the powerful CMV promoter (6,7) drives expression of both the packaging components and the genome. These plasmids also contain the SV40 origin of replication. The simultaneous introduction of these plasmids into a cell line expressing the SV40 large T antigen followed by sodium butyrate treatment produced helper-free retrovirus stocks with titers of ~ 10 7 infectious units/ml at 48 h post-transfection, which were significantly higher than those obtained using vectors driven by the viral 5' LTR and are as high as dedicated/selected cell lines expressing all three components
MATERIALS AND METHODS

Cell lines
NIH 3T3 and 293T (293ts/A16O9) (8) cells were maintained in Dulbecco's modified Eagle's medium (GIBCO) containing 10% (v/v) fetal calf serum and supplemented with antibiotics 293T cells were obtained from D. Baltimore (Rockefeller University)
Construction of expression plasmids
The standard gag-pol and env plasmids from which we derived our molecules were pgag-polgpt (9) and penv (9) . Both plasmids express the viral components from the MLV 5' LTR and pgag-polgpt additionally contains an SV40 origin of replication (on) and a gpt selectable marker The retroviral genome vectors used were pLNSX (10), which carries neomycin resistance (neo) and pLZSN (11) , which carries neo and lacZ genes. All of these plasmids were obtained from A D. Miller (Fred Hutchinson Cancer Research Center) These original plasmids were modified to produce a set of plasmids containing the SV40 on A 350 bp BamH\-HindU\ * To whom correspondence should be addressed fragment carrying the SV40 on was inserted into the BamHlHindYW sites in the backbone of the retroviral vector pXTl (12) (Stratagene). This intermediate molecule, designated pRV51, was created to facilitate the introduction of the SV40 on into any retroviral vector A backbone £coRI-///ndIII fragment from pRV51 containing the SV40 on was used to replace the £coRI-//indIII penv backbone sequences to create plasmid pRV 106 (Fig. 1 A) . The backbone sequences of pRV51 were also used to construct a uni versal plasmid which functions as a cassette to insert the S V40 ori and to replace the viral promoter within the 5' LTR with the CMV promoter (see below) in a number of retroviral vectors, such as pLNCX (10) , which contain neither element. This universal plasmid was also used to construct the CMV promoter-driven vectors for pLNSX and pLZSN (see below), although both already contain the SV40 on sequences. Therefore, the backbone sequences of pLNSX and pLZSN were also replaced with the backbone of pRV51, thereby encoding two SV40 ori sequences in the same plasmid. The Seal site in the backbone ampiciJlin gene and the Kpnl site in the 3' LTR of pRV51, pLNSX and pLZSN were used to insert the backbone sequences of pRV51 into the vector genomes, producing plasnuds pRVl 13 and pRVl 14 (Fig 1 A) .
Expression plasmid pHIT60 is a CMV-dnven gag-pol expression plasmid and prflT50 and pHTT 123 are CMV-dri ven ecotropic env expression plasnuds (Figs 1A and 3A) All three plasnuds contain the SV40 ori. Plasmid pGWIHG is a CMV-promoter expression plasmid containing intron A (13) and the SV40 ori. A 2.3 kb EcoKl-Narl fragment containing the CMV promoter plus intron A unit was excised from pGWIHG, the Nari end was converted to an EcoRl end with a linker and the resulting fragment was used to replace the MLV promoter in pgag-polgpt to produce pHIT60. For pHIT50, the 2.4 kb £coRI fragment from penv containing the ecotropic envelope gene was inserted directly into the £coRI site of pGWIHG. pHIT123 was created to remove the 3' LTR sequences found in pHIT50. A PCR reaction was performed on penv to isolate the pl5e env sequences, creating a BamHl and EcoKl site immediately after the env stop codon The 570 bp Ncol-EcoRl fragment (coordinates 7228-7723) (14) from the PCR product was used to replace the Ncol-EcoRl fragment containing the 3' end of the env and the 3' LTR sequences in pHIT50.
The retroviral vectors were manipulated to replace the entire 5' U3 region with the CMV promoter while preserving the authentic RNA start site at the beginning of the MSV R region. A double-stranded oligonucleotide was constructed to span the junction from the Sad site at -13 in the CMV promoter to the Kpn\ site at +36 in the MSV R sequence (Fig. IB) and inserted into the cloning vector pSP46 (15) . The remaining CMV promoter sequences were restored by inserting the 531 bp Xbal-Sacl fragment from pKV461 (16) into pSP46, upstream of this synthetic oligonucleotide. This heterologous 5' unit was excised from pSP46 using the Pvul site in the backbone ampicillin gene and the Kpnl site at the end of the oligonucleotide fragment This was joined to the Pvul-Kpnl backbone fragment of pRV51 using the Pvul site in the ampicillin gene and the Kpnl site in the 3' retrovira] LTR to create plasmid pRV109 This plasmid functions as a general cassette for the introduction of retroviral vector sequences utilizing the Kpnl sites in the 5' and 3' LTRs. The vector sequences from pLNSX and pLZSN were inserted into pRV109 in this manner. A CMV promoter-driven vector in which the luc gene was inserted into pLNCX has also and their CMV promoter-driven counterparts (pHIToO, pHTTSO, pHTTl 10 and pHUl 11) All plasrnids contain SV40 origins of replication pRV106 and pHTT50 contain the ecotropic envelope sequences from plasmid penv pRV 113 and pHIT 110 are denved from the retroviral vector pLNSX (10) , and pRV 114 and pHTT 111 are derived from pLZSN (II) (B) The DNA sequence around the transcnpuonal start site for pWTl 10 and pHTTl 11 is shown. The ohgonucleoade constructed to span the sequence from the Sac\ site in the CMV promoter to the Kpnl site in the rctroviral R region is boxed Also shown are the positions of trie primers used in the pnmer extension analysis of the transcnptional start site (Fig 2) been similarly constructed (data not shown). The CMV promoterdriven vector derived from pLNSX was designated pHITl 10 and the vector derived from pLZSN was designated pHTTlll (Fig.  1A ).
Transient transfections, infections and determination of viral titer
Transient transfections were performed on 293T cells by overnight calcium phosphate treatment (17) on 10 cm dishes seeded the previous day to give a maximum of 70% confluence/ plate on the day of transfection. Ten micrograms of each plasmid (30 jig total) was used for each transfection. Transfection efficiencies of the 293T cells were routinely 70-90%, as determined using a ZacZ-containing vector plasmid. The transfected cells were incubated for 15-17 h, after which the medium was replaced with 5 ml of fresh medium. Unless otherwise indicated, the viral supernatants were harvested 48 h after fragment carrying the SV40 ori was inserted into the BamHlHindUl sites in the backbone of the retroviral vector pXTI (12) (Stratagene). This intermediate molecule, designated pRV51, was created to facilitate the introduction of the SV40 ori into any retroviral vector. A backbone EcoRl-HindHl fragment from pRV51 containing the SV40 ori was used to replace the EcoRl-Hindm penv backbone sequences to create plasmid pRV106 ( Fig. 1 A) . The backbone sequences of pRV51 were also used to construct a universal plasmid which functions as a cassette to insert the S V40 ori and to replace the viral promoter within the 5' LTR with the CMV promoter (see below) in a number of retroviral vectors, such as pLNCX (10), which contain neither element. This universal plasmid was also used to construct the CMV promoter-driven vectors for pLNSX and pLZSN (see below), although both already contain the SV40 ori sequences. Therefore, the backbone sequences of pLNSX and pLZSN were also replaced with the backbone of pRV51, thereby encoding two SV40 on sequences in the same plasmid. The Seal site in the backbone ampicillin gene and the Kpnl site in the 3' LTR of pRV51, pLNSX and pLZSN were used to insert the backbone sequences of pRV51 into the vector genomes, producing plasmids pRV113 and pRV114 (Fig. 1A) . Expression plasmid pHTT60 is a CMV-dnven gag-pol expression plasmid and pHTT50 and pHTTl 23 are CMV-driven ecotropic env expression plasmids (Figs 1A and 3A). All three plasmids contain the SV40 ori. Plasmid pGWIHG is a CMV-promoter expression plasmid containing intron A (13) and the SV40 ori. A 2.3 kb EcoRl-Narl fragment containing the CMV promoter plus intron A unit was excised from pGWIHG, the Narl end was converted to an EcoRI end with a linker and the resulting fragment was used to replace the MLV promoter in pgag-polgpt to produce pHIT60. For pHIT50, the 2.4 kb EcoRI fragment from penv containing the ecotropic envelope gene was inserted directly into the EcoRI site of pGWIHG. pHIT123 was created to remove the 3' LTR sequences found in pHIT50. A PCR reaction was performed on penv to isolate the pl5e env sequences, creating a BamHl and EcoRI site immediately after the env stop codon. The 570 bp Ncol-EcoRl fragment (coordinates 7228-7723) (14) from the PCR product was used to replace the Ncol-EcoRl fragment containing the 3' end of the env and the 3' LTR sequences in pHIT50.
The retroviral vectors were manipulated to replace the entire 5' U3 region with the CMV promoter while preserving the authentic RNA start site at the beginning of the MSV R region. A double-stranded oligonucleotide was constructed to span the junction from the Sacl site at -13 in the CMV promoter to the Kpnl site at +36 in the MSV R sequence (Fig. IB) and inserted into the cloning vector pSP46 (15) . The remaining CMV promoter sequences were restored by inserting the 531 bp Xbal-Sacl fragment from pKV461(16) into pSP46, upstream of this synthetic oligonucleotide. This heterologous 5' unit was excised from pSP46 using the Pvul site in the backbone ampicillin gene and the Kpnl site at the end of the oligonucleotide fragment This was joined to the Pvul-Kpnl backbone fragment of pRV51 using the Pvul site in the ampicillin gene and the Kpnl site in the 3' retroviral LTR to create plasmid pRV109. This plasmid functions as a general cassette for the introduction of retroviral vector sequences utilizing the Kpnl sites in the 5' and 3' LTRs. The vector sequences from pLNSX and pLZSN were inserted into pRV109 in this manner. A CMV promoter-driven vector in which the luc gene was inserted into pLNCX has also been similarly constructed (data not shown). The CMV promoterdriven vector derived from pLNSX was designated pHTTl 10 and the vector derived from pLZSN was designated pHTTlll (Fig.  1A) .
Transient transfections were performed on 293T cells by overnight calcium phosphate treatment (17) on 10 cm dishes seeded the previous day to give a maximum of 70% confluence/ plate on the day of transfection. Ten micrograms of each plasmid (30 ng total) was used for each transfection. Transfection efficiencies of the 293T cells were routinely 70-90%, as determined using a focZ-containing vector plasmid. The transfected cells were incubated for 15-17 h, after which the medium was replaced with 5 ml of fresh medium. Unless otherwise indicated, the viral supernatants were harvested 48 h after transfection, filtered through 0 45 ^un filters and titered by infection on NIH 3T3 cells. NIH 3T3 cells were plated onto six-well culture dishes at a density of 1-2 x 1(P cells/well the day before infection. Supernatant (1 ml at appropriate dilutions of the original stock) was added to each well with 8 ug/ml Polybrene (Sigma) and incubated for 2 h, followed by the addition of 1 ml of fresh medium Twenty four hours later the cells were split 14 and seeded onto 5 cm dishes. Viral titer was determined by selection in 400 ng/ml G418 (GIBCO) or by X-gal staining. For G418 selection, the medium was replaced every 3 or 4 days and the resistant colonies were counted 10-15 days post-infection by fixing and staining with 0.3% crystal violet in 70% methanol. X-gal staining was performed 24 h following the 1:4 split as previously described (18) . Virus titer was determined by multiplying the total number of G418-resistant colonies (or fj-galactosidase-positive cells) by two, to account for the 2-fold increase in cells during the infection period and the 1:4 split
Sodium butyrate (NaB) inductions
NaB was prepared as a 500 mM stock solution, pH 7.0, sterilized by filtration and added directly to the medium after removal of the calcium phosphate-DNA co-precipitate at final concentrations of 2, 5, 7 and 10 mM. The cells were treated for 12-14 h, washed with PBS to remove any contaminating NaB and refed with 5 ml of fresh medium. Viral supematants were harvested 12 h later (48 h post-transfection) and subsequently harvested at 60, 72 and 84 h after transfection. Viral supematants were titered on NIH 3T3 cells as described above. Control plates were transfected without NaB and harvested 48 h post-transfection.
Helper virus assays
Transfections were carried out on 293T cells as described above and undiluted viral supematants were used to infect NIH 3T3 cells. All infections were performed in the presence of 8 (ig/ml Polybrene (Sigma). The NIH 3T3 cells were passaged every 4-5 days, when the culture supematants were filtered and used to infect fresh NIH 3T3 cells. These cells were selected in G418 for up to 10-15 days to assay for the presence of replication-competent virus. In addition, a marker rescue assay was performed using NIH 3T3 cells harboring an integrated lacZ vector derived from pHITlll. These cells were infected with 1 ml of the culture supematants from the infected NIH 3T3 cells. Twenty four hours later the supematants were removed and the cells were incubated with 1 ml of fresh medium for another 24 h. Supematants from these cultures were then used to infect fresh NIH 3T3 cells which were stained for fJ-galactosidase activity 24 h later.
Primer extension analysis
Total RNA was extracted from 293T cells and analyzed by pnmer extension, essentially as previously described (19) . An oligonucleotide complementary to the 5' U5 region of the retroviral vector and located 112 bases from the predicted RNA start site (Fig. IB) was end-labeled with [f 32 P]ATP (5000 Ci/mmol; Amersham) and hybridized to 10 |ig total RNA at 37°C in 40 mM PIPES, pH 6.5, 0.4 M NaCl, 1 mM EDTA for 16 h. Primer extension was carried out at 42°C for 1 h with 10-15 U/sample AMV reverse transcriptase (Pharmacia). The primer extension products were analyzed on a 6% denaturing polyacrylarrude gel, alongside a sequencing reaction performed on pRV109 with a primer hybridizing within the CMV promoter between -82 and -63 (Fig. IB) 
RESULTS
Three-plasmid co-transfections to generate retrovirus stocks
In the first instance, we transfected a standard set of gag-pol, env and vector genome plasmids into 293T cells and titered the resulting viruses on NIH 3T3 cells. The original packaging components used were pgag-polgpt (9), a gag-pol expression vector and penv (9) , an ecotropic envelope expression vector. In both plasmids, expression of the viral components is driven by the MLV LTR promoter. The retroviral vector genomes used were pLNSX (10), which carries a neomycin resistance gene, and pLZSN (11) , which carries neomycin resistance and a lacZ gene. When these original plasmids were co-transfected into the highly transferable 293T cells, we produced retrovirus stocks with titers of 1.4 x 10 4 c.f.uiml for vector pLNSX and 9.8 x 10 3 l.f.uVml (as assayed by staining for ^-galactosidase) to 1.1 x 10 4 c.f.u7ml (G418 selection) for vector pLZSN ( Table 1 ). The slightly lower titers obtained by the vector genome pLZSN have been noted previously (11) .
Addition of SV40 ori sequences and the CMV promoter boosts viral titers
293T cells express the SV40 large T antigen (8) , which increases the copy number of plasmids containing the SV40 ori. This 2) were analyzed on a 6% denaturing polyacrylamide gel, alongside a sequencing reaction performed on pRV 109 with a primer hybridizing within the CMV promoter between -82 and -63 (Fig. 1B) . The primer extended to yield a 112 base product (arrowed) which corresponds to the distance to the predicted start site of the retroviral transcript.
template amplification has been previously used to increase retrovirus titers by transient transfection of COS-7 cells (5). We therefore decided to reproduce this observation with the specific system used here. An SV40 ori was inserted into penv, pLNSX and pLZSN to produce plasmids pRV106, pRVl 13 and pRVl 14 respectively (Fig. 1A) . Co-transfection of pgag-polgpt, pRV106 and pRVl 13 or pRVl 14 into 293T cells increased the infectious titer by at least 14-fold compared to the original set of plasmids, producing more than 10 5 infectious units/ml (Table 1) . As before, the titers obtained from the neo-lacZ vector pRV114 were slightly lower than those obtained with the neo vector pRVl 13. The placement of two SV40 ori sequences in pRV113 and pRVl 14 (see Materials and Methods) did not significantly alter the virus titers, as comparable titers were obtained when pgag-polgpt, pRV106 and pRV114 or pLZSN were co-transfected (data not shown).
In a further attempt to boost the titers, we decided to improve expression of the packaging components by placing the gag-pol and env genes under the control of the powerful CMV promoter. Expression plasmids pHIT60 and pHIT50 are similar to pgagpolgpt and pRV106 respectively, except that the viral genes are under the control of the CMV promoter (Fig. 1 A) . Transfection of pHIT60, pHIT50 and pRVl 14 into 293T cells produced virus stocks with a higher titer of 3 x 10 5 l.f.u./ml, compared to the titer of 7 x 10 4 l.f.u./ml obtained when all three components were driven by the retroviral promoter (Table 1) .
Despite the improvements made in retrovirus titer by the incorporation of the CMV promoter into the packaging components, we speculated that the level of vector genome RNA may be limiting the titers in this system. To address this possibility, we constructed CMV promoter-driven retroviral vectors. These retained the authentic RNA start site to ensure correct reverse transcription of the vector genome following infection. An oligonucleotide was designed to precisely place the transcriptional start site for the CMV promoter at the +l position found at the boundary of the U3/R sequences of the retroviral genome vectors (Fig. IB) . Both pLNSX and pLZSN were placed under the control of the CMV promoter and the resulting molecules were designated pHIT 110 and pHIT 111 respectively (Fig. 1) . The correct start site for transcription of the retroviral genome was confirmed by primer extension analysis on total RNA extracted from 293T cells transfected with pHITl 10 (Figs 1 and 2 ). Co-transfection of all three CMV promoter-SV40 ori constructs, the pHIT plasmid series, generated the highest titers, which were in excess of 10 6 infectious units/ml (Table I ). In keeping with our previous observations, pHITHO generated slightly higher titers than pHITl 11. At present, the cause of this effect is not clear, but it may be that the larger lacZ-neo transcript is packaged less efficiently. We are currently exploring the vector containing the smaller luc reporter gene as a means to overcome this disadvantage. The direct comparison of infectious titers from transfections with pHIT60, pHIT50 and pHITlll as the vector genome (1.4 x 10 6 l.f.u./ml) versus pRV 114 as the vector genome (3 x 10 5 l.f.u./ml) confirmed that expression of the vector genome by the CMV promoter increased virus titers (Table 1) . We further quantitated virus titers obtained from various combinations of the LTR-and CMV-driven cassettes (Table 1 ). These studies confirmed that it was necessary to have all three components driven by the CMV promoter in order to achieve the highest titer retroviral stocks. The use of any one LTR plasmid reduced the titers accordingly. Similar relative titers were also obtained using COS-1 cells, although levels were ~ 10-fold lower across all constructions (data not shown).
Elimination of helper virus by removal of 3' overlapping regions
We examined the supematants from transfected 293T cells for the presence of contaminating replication-competent virus or helper virus. Undiluted supematants of the highest titer retroviral stocks produced by co-transfection of 293T cells with pHIT60, pHIT50 and pHITHO were used to infect NIH 3T3 cells and these cells were then passaged for 4 weeks to allow virus spread. At each passage, the culture supematants were harvested, filtered and used to infect fresh NIH 3T3 cells. These cells were selected in G418 for up to 10 days to assay for the presence of replicationcompetent virus harboring the neo gene
In addition, we used a sensitive marker rescue assay for the detection of helper virus by using an NIH 3T3 cell line stably transduced with pHITlll, which is similar to the previously reported BAG cell line (20) . The integrated /acZ-containing genome in these cells can be rescued by transfection of the cells with the retroviral packaging components on plasrruds pHIT60 and pHIT50 (data not shown). Medium from NIH 3T3 cells infected with supematants from the transfected 293T cells was used to infect this cell line. Forty eight hours later, the supematants from the cell line were filtered and used to infect fresh NIH 3T3 cells, which were then stained for pVgalactosidase activity 24 h later. Any pVgalactosidase-positive cells appearing at this stage are due to lacZ genomes that had been rescued from the pHITl 11 cell line by helper virus.
In a recent report by Pear et al. (21) , replication-competent virus was found following three-plasmid co-transfection into 293T cells, although Landau and Littman (5) did not detect any replication-competent virus following transfection of COS-7 cells. We have detected helper virus at 10 days post-infection using both of the above assays. However, we have identified a small region of the 3' LTR present in penv and pHIT50 that is homologous to the vector genomes and which may contribute to helper virus formation through three recombination events of our input plasmids. To eliminate the possibility of this occurring, we have removed the homologous overlap in pHIT50 by isolating only the pl5e env sequences by PCR and replacing the corresponding sequences in pHTT50 containing the 3' end of the env sequence and the 3' LTR. The new CMV promoter-driven env expression plasmid lacking the homologous 3' LTR sequences was designated pHITI23 (Fig. 3A) . When the two helper virus assays were repeated using plasmids pHIT60, pHIT123 and pHITl 10, G418-resistant colonies and rescue of the lacZ gene were undetectable even after 8 weeks of passage (Fig. 3B) .
Maximizing virus titers from transient transfections withNaB
We have so far demonstrated that increases in virus titers were achieved by the use of S V40 on-containing plasmids and by using the CMV promoter to drive both the structural and vector components of the system. The use of chloroquine, although recommended by Pear et al. (21) , did not increase our titers on 293T cells (data not shown). We did, however, see a dramatic increase in virus titer after treatment of the transfected cells with NaB (Fig. 4) . NaB has been shown to increase the percentage of cells expressing exogenous DNA (22) , possibly through its effect on the cell cycle (23) or by inducing erythroid differentiation in hematopoietic cell lines (24) (25) (26) . The effect of NaB on gene expression has also been shown to be enhancer dependent (22) and a number of eucaryotic promoters are activated by NaB, including the CMV promoter (27, 28) . NaB inductions were therefore performed on 293T cells transfected with pHIT60, pHIT123 and pHTTl 10 or pHITl 11 using NaB at final concentrations of 2, 5, 7 and 10 mM. Figure 4 shows the average titers from two independent experiments determining the optimal time to harvest the supematants and the NaB concentration which induced the highest uters In every case titers peaked at 48 h post-transfection, but infectivity was greatly reduced at 60 h and titers were at least one log lower by 72 h post-transfection. A final concentration of 10 mM NaB enhanced viral titers by almost a log Without NaB treatment, pHTT60, pHIT123, pHJTl 10 gave a titer of 1.2 x 10 6 c.f.uVml and pHIT60, pHTT123, pHITl 11 gave 2.5 x 10 5 l.f.uiml as compared with 9.6 x 10 6 c.fuJml (Fig. 4A ) and 5.6 x 10 6 l.f uVml (Fig 4B) respectively after induction with 10 mM NaB.
Passive DNA transfer and retrofection
The use of relatively high amounts of DNA in the 293T transfections raises the possibility that DNA may be transfered in the infection assay or that plasmid-encoded RNA may be transfered by non-specific retrofection. To test the first possibility, 10 u.g of pHITl 11 or pSV2neo (29) were transfected into 293T cells and the supematants were harvested and used to 'infect' NIH 3T3 cells as described above. The 'infected' NIH 3T3 cells were selected in 400 |ig/ml G418 for 10-15 days but no resistant colonies were observed (data not shown) Although free DNA may be carried over onto NIH 3T3 cells, it does not passively enter the cells and produce artificially high titers. In retrofection, non-retroviral RNAs become encapsidated into the retroviral particles and become reverse transcribed upon infection (30,31)-To test this possibility, pHIT60 and pHIT123 were transfected into 293T cells with either pHIT 111 (a retroviral vector genome), pPE346 (a non-retroviral CMW-lacZ plasmid) (32) or pMW41 (a non-retroviral CMV-luc plasmid derived from pMW 16 (33) into which the SV40 ori was inserted). As expected, co-transfection of pHIT60, pHIT123 and pHITlll produced titers of 10 5 1 f.uVml without NaB treatment, whereas no /acZ-positive clones were seen with pPE346 and no luciferase activity was detected with pMW41. Therefore, the titers achieved using the HIT vectors are not due to the entry of free DNA into the cells by binding to virus particles nor to the non-specific encapsidation of RNAs.
DISCUSSION
We have reported here a new system for the production of high titer helper-free retroviral stocks by transient transfection. Under the optimized conditions described using the 293T cell line we achieved titers neanng 10 7 infectious units/ml at 48 h post-transfection. The viral stocks produced were helper virus-free, as no helper virus could be detected even after 8 weeks of passage. This system could be used for the transduction of cell lines or for the rapid screening of MLV gag-pol or env mutants.
In order to achieve maximum titers from retrovirus stocks by transient transfection, it is necessary to increase either or both viral gene expression and transfection efficiency of the producer cells In an approach similar to that of Landau and Littman (5), we boosted gene expression in the first instance by the combined use of SV40 ori sequences in all the retroviral components and host cells expressing the SV40 large T antigen. 293T cells were used as they have previously been reported to be highly transferable (21) . We further improved gene expression of the packaging components {gag-pol and env) in the system by directing their expression from the CM V promoter. We have also demonstrated that driving transcription of the vector genome from the CMV promoter further increased infectious titers. The highest titers were obtained when all three components were on CMV-driven plasmids and the use of any one component driven by the LTR limited the infectious titer. This appeared especially true for the env component in the system, as expression of this gene from the LTR promoter had the most severe effect on the infectious titer of the virus stock. Finally, a study was undertaken to maximize the yields of virus by inducing expression of the CMV promoter-driven plasmids with NaB.
When the virus stocks were screened for helper virus, helper virus was initially detected in virus stocks generated using the CMV promoter-dnven env expression vector pHIT50. This plasmid contains a small region of the 3' LTR that creates a homologous overlap with the vector genomes. Removal of this homologous overlap effectively eliminated helper virus formation. This is the first reported method for obtaining -107 helper-free viral stocks without the need to establish and maintain packaging cell lines or stable producer lines, thereby allowing rapid characterization of gag-pol and env mutants and producing high titer retroviral vectors for transduction by a convenient, rapid and reproducible method. During the course of this work, a similar system was reported (34) , although titers appeared to be somewhat lower. We have also developed a CMV promoterdriven amphotropic envelope system that may have applications in human gene therapy.
